FY2024 Earnings Forecast for AQST Issued By Leerink Partnrs

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Leerink Partnrs increased their FY2024 earnings per share estimates for shares of Aquestive Therapeutics in a research report issued on Tuesday, November 5th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will post earnings per share of ($0.47) for the year, up from their previous estimate of ($0.50). The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.48) per share. Leerink Partnrs also issued estimates for Aquestive Therapeutics’ Q4 2024 earnings at ($0.14) EPS.

Several other research analysts have also issued reports on AQST. Leerink Partners raised their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. JMP Securities reissued a “market outperform” rating and set a $9.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research note on Wednesday. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Aquestive Therapeutics has a consensus rating of “Buy” and a consensus price target of $9.80.

Aquestive Therapeutics Stock Up 7.5 %

Shares of AQST stock opened at $5.46 on Friday. The firm has a 50 day moving average of $4.94 and a 200-day moving average of $3.85. The company has a market cap of $497.19 million, a price-to-earnings ratio of -12.13 and a beta of 2.82. Aquestive Therapeutics has a 52 week low of $1.55 and a 52 week high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same period in the prior year, the company earned ($0.03) earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AQST. Janney Montgomery Scott LLC bought a new stake in shares of Aquestive Therapeutics during the first quarter worth about $1,456,000. SG Americas Securities LLC bought a new stake in Aquestive Therapeutics during the 1st quarter worth approximately $54,000. Vanguard Group Inc. increased its holdings in Aquestive Therapeutics by 71.7% during the 1st quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock worth $13,813,000 after purchasing an additional 1,353,518 shares in the last quarter. Lazard Asset Management LLC raised its stake in shares of Aquestive Therapeutics by 115.5% in the first quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after purchasing an additional 15,601 shares during the last quarter. Finally, Virtu Financial LLC lifted its holdings in shares of Aquestive Therapeutics by 219.7% in the first quarter. Virtu Financial LLC now owns 102,836 shares of the company’s stock valued at $438,000 after purchasing an additional 70,666 shares in the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.